IP Library Granted Patent US 7,223,561
Granted Patent B2
US 7,223,561 · App. 10/873,504 · Granted May 29, 2007

Process of high purity albumin production

Assignee: Novozymes Delta, Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,223,561
App. No.
10/873,504
Granted
May 29, 2007
Kind
B2
Abstract

A process is provided for the preparation of albumin which has extremely low levels of or is essentially free of colorants, metal ions, human proteins, host proteins, fragments of albumin, polymers or aggregates of albumin and viruses, and which is essentially non-glycated, relatively high in free thiol and with an intact C-terminus. The process comprises passing albumin (preferably expressed and secreted by transformed yeast) through positive mode cation exchange and then positive mode anion exchange chromatography. Other steps may also be employed, ultrafiltration, gel permeation chromatography, affinity chromatography binding the albumin by using blue dyes) and affinity chromatography binding contaminants by using an aminophenylboronic acid resin. Elution of albumin, with a compound having affinity for albumin, from a material having no specific affinity for albumin is also disclosed, as is removal of ammonium ions with a counter-ion.

Claims (9)

1. A process for purifying albumin from a yeast culture medium obtained by culturing yeast transformed with an albumin-encoding nucleotide sequence in a fermentation medium, whereby said yeast expresses and secretes albumin, the process comprising the steps of:

(a) separating the yeast from the culture medium to yield an albumin solution;

(b) conditioning the albumin solution from step (a) by adding octanoate to a final concentration of from about 1 to about 10 mM and adjusting the pH so that it is from about 4.0 to about 5.0;

(c) subjecting the albumin solution from step (b) to cationic exchange chromatography in which the albumin is bound to a cation exchange material and eluting the bound albumin from the material by applying a solution of a compound having a specific affinity for albumin;

(d) subjecting the albumin eluted from the cation exchange material without any intervening treatment or without any intervening treatment other than dilution to anion exchange chromatography in which the albumin is bound to an anion exchange material and the albumin is eluted from the anion exchanger with a buffer containing from about 50 to about 200 mM boric acid salt;

(e) ultrafiltering the albumin-containing solution obtained thereby through an ultrafiltration membrane to obtain an ultrafiltration retentate having an albumin concentration of at least about 80 grams of albumin per liter and diafiltrating the ultrafiltration retentate against at least five retentate equivalents of a salt solution;

(f) sterilizing the albumin containing retentate resulting from the diafiltration of step (e) by sterile filtration; and

(g) filling a formulation vessel with the sterile filtered albumin product of step (f).

2. A process according to claim 1 wherein the compound having a specific affinity for albumin is a faffy acid salt.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 26, 2011
From: NOVOZYMES BIOPHARMA UK LIMITED
To: NOVOZYMES BIOPHARMA DK A/S
Reel/Frame 026813/0938 →
CHANGE OF NAME Recorded Aug 25, 2011
From: DELTA BIOTECHNOLOGY LIMITED
To: NOVOZYMES BIOPHARMA UK LIMITED
Reel/Frame 026808/0549 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 9, 2008
From: SLEEP, DARRELL; VAN URK, HENDRIK; BEREZENKO, STEPHEN; WOODROW, JOHN RODNEY; JOHNSON, RICHARD ALAN; WOOD, PATRICIA CAROL; BURTON, STEPHEN JAMES; QUIRK, ALAN VICTOR
To: DELTA BIOTECHNOLOGY LIMITED
Reel/Frame 021947/0805 →
CHANGE OF NAME Recorded Dec 8, 2008
From: DELTA BIOTECHNOLOGY LIMITED
To: NOVOZYMES DELTA LIMITED
Reel/Frame 021936/0283 →
CHANGE OF NAME Recorded Jun 30, 2008
From: NOVOZYMES DELTA LIMITED
To: NOVOZYMES BIOPHARMA UK LIMITED
Reel/Frame 021172/0027 →
Continuity (4)
Continuation 1030135700 · Nov 21, 2002
Continuation 0895255800 · Feb 24, 1999
Continuation In Part 0837885900 · May 25, 1995
Related Publication 20050142636A1 · Jun 30, 2005